Interleukin 17F level and interferon beta response in patients with multiple sclerosis

June 3, 2013 ? A study by Hans-Peter Hartung, M.D., of Heinrich-Heine-Universit?t, D?sseldoft, Germany, and colleagues examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis. (Online First)

Serum samples were analyzed with an immunoassay from 239 randomly selected patients treated with interferon beta-1b, 250 micrograms, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study. Researchers measured the levels of IL-17F at baseline and month 6, as well as the difference between the IL-17F levels at month 6 and baseline were compared between: (1) patients with less disease activity versus more disease activity; (2) patients with no disease activity versus some disease activity; and (3) responders versus nonresponders.

According to study results,levels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging (MRI) criteria. Relapses and new lesions on MRI were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change.

"We found that serum concentrations of IL-17F alone did not predict response to interferon beta-1b therapy in patients with relapsing-remitting multiple sclerosis." The study concludes, "Given the multifaceted pathophysiology associated with disease progression and response to treatment by patients with relapsing-remitting multiple sclerosis, using extreme patient cohorts in combination with immune-based biomarker signatures may actually be the most efficient way of initially identifying response markers."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by The JAMA Network Journals.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Journal Reference:

1. Hans-Peter Hartung et al. Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. JAMA Neurol, 2013 DOI: 10.1001/.jamaneurol.2013.192

Note: If no author is given, the source is cited instead.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/top_health/~3/jXfeK00zZQg/130603164153.htm

news 10 hillary rosen j.k. rowling j.k. rowling axl rose google earnings pat burrell